188 related articles for article (PubMed ID: 18038215)
21. Cardiovascular events and COX-2 inhibitors.
McGeer PL; McGeer EG; Yasojima K
JAMA; 2001 Dec; 286(22):2810; author reply 2811-2. PubMed ID: 11735747
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Patrono C
Haematologica; 2002 Jan; 87(1):6-8. PubMed ID: 11801459
[No Abstract] [Full Text] [Related]
23. An international scientific meeting on aspirin is needed.
Morgan G
J Epidemiol Community Health; 2003 May; 57(5):314. PubMed ID: 12700207
[No Abstract] [Full Text] [Related]
24. [Aspirin. A wonder drug?].
Diez-Ewald M
Invest Clin; 1997 Jun; 38(2):59-61. PubMed ID: 9296640
[No Abstract] [Full Text] [Related]
25. Cardioprotective effects of aspirin compromised by other NSAIDs.
Gottlieb S
BMJ; 2003 Sep; 327(7414):520. PubMed ID: 12958094
[No Abstract] [Full Text] [Related]
26. [Aspirin and prevention of cardiovascular risk].
Karila-Cohen D; Gabriel Steg P
Rev Med Interne; 2000 Mar; 21 Suppl 1():35s-40s. PubMed ID: 10763203
[TBL] [Abstract][Full Text] [Related]
27. [Aspirin and hemostasis].
Samama MM; Elalamy I
Rev Med Interne; 2000 Mar; 21 Suppl 1():27s-34s. PubMed ID: 10763202
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease.
Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG
Int J Cardiol; 2011 Jul; 150(1):39-44. PubMed ID: 20207433
[TBL] [Abstract][Full Text] [Related]
29. Current perspective on the cardiovascular effects of coxibs.
Konstam MA; Weir MR
Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
[TBL] [Abstract][Full Text] [Related]
30. Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects.
Stepensky D; Rimon G
Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):41-52. PubMed ID: 25307725
[TBL] [Abstract][Full Text] [Related]
31. Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study.
Rothschild BM
Reumatismo; 2004; 56(2):89-93. PubMed ID: 15309216
[TBL] [Abstract][Full Text] [Related]
32. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
[TBL] [Abstract][Full Text] [Related]
33. The mechanism of action of aspirin.
Vane JR; Botting RM
Thromb Res; 2003 Jun; 110(5-6):255-8. PubMed ID: 14592543
[TBL] [Abstract][Full Text] [Related]
34. [Immortal aspirin....].
Devulder B
Rev Med Interne; 2000 Mar; 21 Suppl 1():5s-7s. PubMed ID: 10763199
[No Abstract] [Full Text] [Related]
35. [Aspirin and cerebral ischemic accidents].
Crassard I; Niclot P; Bousser MG
Rev Med Interne; 2000 Mar; 21 Suppl 1():41s-49s. PubMed ID: 10763204
[TBL] [Abstract][Full Text] [Related]
36. [Cyclooxigenase-1 gene polymorphism and aspirin resistance].
Bondar' TN; Kravchenko NA
Tsitol Genet; 2012; 46(4):66-72. PubMed ID: 23074965
[TBL] [Abstract][Full Text] [Related]
37. Clinical use of aspirin in ischemic heart disease: past, present and future.
De Caterina R; Renda G
Curr Pharm Des; 2012; 18(33):5215-23. PubMed ID: 22724410
[TBL] [Abstract][Full Text] [Related]
38. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin.
Patrono C
J Am Coll Cardiol; 2015 Jul; 66(1):74-85. PubMed ID: 26139061
[TBL] [Abstract][Full Text] [Related]
39. [Aspirin].
Reinhart WH
Ther Umsch; 1999 Dec; 56(12):713-7. PubMed ID: 10638278
[TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase Inhibitors and Cancer: The Missing Pieces.
Patrono C
J Pharmacol Exp Ther; 2023 Aug; 386(2):181-189. PubMed ID: 37280092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
